Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–65 of 65 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systolic Dysfunction Clear all

Conditions: Heart Failure, Reduced Ejection Fraction
Interventions: sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more

Conditions: Peripartum Cardiomyopathy, Diastolic Dysfunction
Interventions: A clinical Transthoracic echocardiogram; Diagnostic Test
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
Interventions: Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 38
States / cities: Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more

Conditions: Hypertension
Interventions: Intensive control of SBP, Standard control of SBP; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 50 Years and older
Enrollment: 9,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cardiomyopathy, Hypertrophic
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Systolic Heart Failure (Dilated Cardiomyopathy)
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions: Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines); Behavioral · Drug
Lead sponsor: Wayne State University; Other
Eligibility: 35 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Diastolic Dysfunction, Systolic Dysfunction, Diastolic Heart Failure
Interventions: Sulforaphane; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 60 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Pediatric Heart Failure
Interventions: LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 25
States / cities: Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Isolated Systolic Hypertension, Endothelial Dysfunction
Interventions: 6R-BH4, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure, Asymptomatic Systolic Dysfunction
Interventions: Nesiritide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sleep Apnea, Obstructive, Hypoxia, Hypercapnia, Sleep Disorders, Obesity, Hypertension, Coronary Artery Vasospasm, Right Ventricular Overload, Left Ventricular Function Systolic Dysfunction, Ventricular Hypertrophy
Interventions: Clinically prescribed CPAP therapy; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Heart Failure
Interventions: Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 34
States / cities: Huntsville, Alabama • Anchorage, Alaska • Redwood City, California + 31 more

Conditions: Heart Failure
Interventions: sacubitril/valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 15
States / cities: Loma Linda, California • Los Angeles, California • Palo Alto, California + 12 more

Conditions: Left Ventricular Dysfunction
Interventions: Adult stem cells, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more

Conditions: Left Ventricular Dysfunction
Interventions: Adult stem cells, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more

Conditions: Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy, Left Ventricular Non-compaction Cardiomyopathy
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

Systolic Blood Pressure Intervention Trial

The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function

"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"

REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

Pediatric Cardiomyopathy Mutation Analysis